CVE-2023-41089
CVE-2023-41089 is a high-severity vulnerability in Dexma Dexgate with a CVSS 3.x base score of 8.0. It is not currently listed as actively exploited by CISA, and its EPSS exploit-prediction score is low. The underlying weakness is classified as CWE-287.
Key facts
- Severity: High (CVSS 3.x base score 8.0)
- EPSS exploit prediction: 1% (40th percentile)
- Actively exploited: Not listed in CISA KEV
- Weakness: CWE-287
- Affected product: Dexma Dexgate
- Published:
- Last modified:
Description
The affected product is vulnerable to an improper authentication vulnerability, which may allow an attacker to impersonate a legitimate user as long as the device keeps the session active, since the attack takes advantage of the cookie header to generate "legitimate" requests.
Frequently asked questions
- What is CVE-2023-41089?
- The affected product is vulnerable to an improper authentication vulnerability, which may allow an attacker to impersonate a legitimate user as long as the device keeps the session active, since the attack takes advantage of the cookie header to generate "legitimate" requests.
- How severe is CVE-2023-41089?
- CVE-2023-41089 has a CVSS 3.x base score of 8.0, rated high severity. It is exploitable over an adjacent network with low attack complexity, requires no privileges and user interaction. Impact on confidentiality is high, integrity high, and availability high.
- Is CVE-2023-41089 being actively exploited?
- It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 1% (40th percentile), an estimate of the probability of exploitation in the next 30 days.
- What products are affected by CVE-2023-41089?
- CVE-2023-41089 affects Dexma Dexgate. See the affected-products list for the exact vulnerable versions.
- How do I fix CVE-2023-41089?
- Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround. Given its high severity, prioritise patching exposed systems.
- When was CVE-2023-41089 published?
- CVE-2023-41089 was published on 2023-10-19 and last updated on 2026-06-17.
References
Affected products (1)
- cpe:2.3:a:dexma:dexgate:20130114:*:*:*:*:*:*:*
More vulnerabilities in Dexma Dexgate
- CVE-2023-41088 — Medium (CVSS 6.3): The affected product is vulnerable to a cleartext transmission of sensitive information vulnerability, which may allow…
- CVE-2023-42435 — Medium (CVSS 5.5): The affected product is vulnerable to a cross-site request forgery vulnerability, which may allow an attacker to…
- CVE-2023-40153 — Medium (CVSS 5.4): The affected product is vulnerable to a cross-site scripting vulnerability, which could allow an attacker to access the…
- CVE-2023-42666 — Medium (CVSS 5.3): The affected product is vulnerable to an exposure of sensitive information to an unauthorized actor vulnerability,…
All CVEs affecting Dexma Dexgate →
Other CWE-287 (Improper Authentication) vulnerabilities
- CVE-2026-45480 — Critical (CVSS 10.0): Improper authentication in Azure Active Directory allows an unauthorized attacker to elevate privileges over a network.
- CVE-2026-46389 — Critical (CVSS 10.0): UDS Identity Config builds the Keycloak configuration image (realm, plugins, theme, truststore, JARs) consumed by UDS…
- CVE-2026-10611 — Critical (CVSS 10.0): An authentication bypass vulnerability exists in MISP when LDAP mixed authentication is enabled with OTP enforcement.…
- CVE-2026-47280 — Critical (CVSS 10.0): Improper authentication in Azure Resource Manager (ARM) allows an unauthorized attacker to elevate privileges over a…
- CVE-2026-42822 — Critical (CVSS 10.0): Improper authentication in Azure Local Disconnected Operations allows an unauthorized attacker to elevate privileges…
- CVE-2026-20182 — Critical (CVSS 10.0): May 2026: This security advisory provides the details and fix information for a vulnerability that was discovered and…
Browse all CWE-287 (Improper Authentication) vulnerabilities →